home

Mallinckrodt boosts buyback plan amid news of a 2,000% price hike on infant drug

EVENTSMallinckrodt2015-11-20 13:06 Read   679

Mallinckrodt's shares have suffered since short seller Citron Research called out the company's pricing policies and marketing efforts last week.

Lilly and Merck Expand Immuno-oncology Collaboration with Phase III Nonsquamous Non-Small Cell Lung Cancer Trial

EVENTSMerck2015-11-20 11:00 Read   289

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's ALIMTA and Merck's KEYTRUDA in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC).

Radius puts off its FDA filing to be 'respectful' of holiday plans

EVENTSBloomberg story2015-11-19 17:17 Read   236

Radius Health's shares slipped on Tuesday after the company said it was postponing a planned FDA filing for its osteoporosis drug.

Warburg puts up $300M to launch a buyout-hungry drug firm

EVENTSWarburg2015-11-19 16:37 Read   189

Private equity giant Warburg Pincus is diving into specialty pharmaceuticals, launching Vertice Pharma and promising to invest up to $300 million in the company as it scouts for buyable assets.

Pharma faces 'challenging and prolonged' reforms in China, with pricing power at risk

EVENTS Reuters2015-11-18 17:37 Read   180

Big Pharma has already seen sales in China slow, thanks in part to stepped-up competition from local drugmakers. Healthcare reform there is also taking its toll.

Activist investor's new advice for Amgen: Merge with Allergan

EVENTSAmgen2015-11-18 16:48 Read   161

Dan Loeb, the activist investor who once called for Amgen ($AMGN) to break itself in two, is now advising the Big Biotech to consider merging with Allergan ($AGN), according to Bloomberg.

Stepped-up Nucynta sales push starts paying off for Depomed

EVENTSDepomed2015-11-17 17:33 Read   265

Depomed's ($DEPO) relaunch of the Nucynta franchise--purchased earlier this year from Johnson & Johnson ($JNJ)--is off to a running start.

Catalent stops production at French plant, brings in law enforcement after it twice detects tampering

EVENTSCatalent2015-11-17 16:29 Read   389

Catalent has halted production at a softgel capsule manufacturing facility in France at the request of regulators after several incidents in which it appears someone within the plant purposely mixed the wrong capsules into batches. The company said it is working with French law enforcement and regulators to find out what happened.

Moving on from Novartis, Array inks a $455M oncology deal with Pierre Fabre

EVENTSArray2015-11-17 15:12 Read   219

Array BioPharma ($ARRY), hunting for partners after Novartis ($NVS) walked away from a pair of cancer projects, has linked up with Pierre Fabre to co-develop the treatments in an agreement worth up to $455 million.

Exclusive: U.S. drug benefit managers clamp down on specialty pharmacies

EVENTSREUTERS2015-11-16 10:01 Read   265

In recent days, the largest U.S. managers of private prescription drug benefits have cut off at least eight pharmacies that work closely with drugmakers, intensifying scrutiny of a system that helps inflate drug prices, officials at the benefit managers told Reuters.

Merck Provides Update on REVEAL Outcomes Study

EVENTSMerck2015-11-16 09:13 Read   205

Merck, known as MSD outside the United States and Canada, today announced that the Data Monitoring Committee (DMC) of the REVEAL outcomes study for anacetrapib has completed its planned review of unblinded study data and recommended the study continue with no changes.

Merck may appeal to Supreme Court after again losing fight to protect Cubicin patents

EVENTSMerck2015-11-15 10:09 Read   242

Merck & Co. ($MRK) is running low on options after a federal appeals court Thursday again declined to back four patents that would have held at bay for 5 more years generics of the antibiotic Cubicin, the drug that was key to its $9.5 billion buyout of Cubist. Next up may be an appeal to the U.S. Supreme Court.